CJ CheilJedang Corporation

CJ CheilJedang Corporation

174,000.00
KRW
+2,200.00
(+1.28%)
-20,865.55EPS
2.72TMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
771,134.09
830,966.08
915,147.87
1,030,424.49
1,165,340.04
1,182,210.39
1,394,371.66
1,513,028.92
1,640,517.84
1,877,061.06
1,810,999.96
1,698,991.13
1,706,616.31
1,708,901.16
Basic EPS, GAAP
8,293
6,530
13,401
19,522
26,179
55,416
9,516
42,783
38,246
37,188
24,081
8,250
-35,668
-42,418.66
Free Cash Flow per Basic Share
-42,874.17
11,245.55
29,504.4
-7,844.42
-25,242.16
-82,487.15
28,644.72
57,999.95
14,925.86
3,795.01
73,667.41
69,665.41
45,559.15
35,773.1
Dividend per Share
2,639.7
2,631.25
2,988.77
3,828.46
2,503.19
3,900.68
5,852
6,592.33
7,109
11,230.14
8,817.15
7,985.29
10,826.93
9,264.27
Book Value per Share
225,897.53
233,125.5
245,018.94
265,742.56
262,747.85
324,979.4
331,651.4
358,426.67
415,522.7
459,217.99
486,151.4
533,509.02
479,827.51
507,667.35
Tangible Book Value per Share
87,407.26
96,071.6
109,298.24
83,477.73
47,600.07
116,096.86
4,355.87
51,048.99
107,954.12
142,249.15
193,007.5
203,753.57
170,451.26
187,344.21
Basic Weighted Avg Shares
14
14
14
14
14
16
16
16
16
16
16
16
16
16
Sales/Revenue/Turnover
10,847,718
11,701,797
12,924,472
14,563,257
16,477,174
18,670,060
22,352,462
24,245,726
26,289,228
30,079,513
29,023,473
27,239,748
27,342,589
27,370,176
Operating Margin (%)
3.18
4.96
5.81
5.79
4.71
4.46
4.01
5.61
5.8
5.53
4.45
5.33
4.51
3.83
Depreciation Expense
381,371
447,615
483,599
531,278
565,960
640,622
1,110,411
1,285,784
1,265,299
1,403,288
1,542,100
1,558,106
1,632,125
1,606,275
Net Income, GAAP
116,660
91,957
189,260
275,910
370,155
875,157
152,546
685,582
612,890
595,930
385,927
132,271
-571,456
-679,388
Effective Tax Rate (%)
43.92
43.27
30.47
33.09
29.36
28.5
43.61
33.27
26.72
35.56
23.57
56.04
365.58
- -
Profit Margin (%)
1.08
0.79
1.46
1.89
2.25
4.69
0.68
2.83
2.33
1.98
1.33
0.49
-2.09
-2.48
Working Capital
-3,851
-149,168
-317,232
181,460
-533,446
-1,157,970
-259,199
387,240
-190,267
38,531
24,607
-1,311,734
-1,564,203
-1,444,388
LT Debt
3,685,473
3,483,578
3,157,199
4,087,457
4,306,074
4,192,256
6,753,421
6,593,796
6,249,736
6,783,092
6,482,180
5,802,989
6,161,395
6,737,405
Total Equity
4,812,579
4,949,880
5,385,233
6,060,477
6,143,853
7,308,212
9,481,480
10,166,439
10,806,800
11,529,023
11,779,942
12,226,876
11,551,203
11,969,899
Return on Invested Capital (%)
1.86
3.04
4.73
4.72
4.2
4.12
2.88
4.59
5.51
4.91
4.28
2.71
-13.87
- -
Return on Capital (%)
2.57
1.46
2.27
2.67
3.63
7.02
1.95
4.06
2.65
2.86
2.63
0.59
-8.58
- -
Return on Common Equity (%)
3.99
3.14
6.19
8.44
10.93
21.49
3.16
13.52
10.78
9.27
5.56
1.77
-7.67
-9.08

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,368,491
5,545,313
5,900,179
LT Borrowings
4,339,814
4,928,344
4,766,292
LT Finance Leases
1,821,581
1,973,917
1,971,113
Preferred Equity and Hybrid Capital
6,637
6,637
6,637
Shares Outstanding
15
15
15
Market Capitalization
3,056,951
3,181,874
2,720,392

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,869,093
9,036,492
8,967,160
Cash, Cash Equivalents & STI
1,386,145
2,242,589
1,731,600
Accounts Receivable, Net
2,919,045
3,128,984
3,107,455
Inventories
2,181,887
2,648,918
2,848,541
Total Current Liabilities
10,433,296
10,078,101
10,411,548
Payables & Accruals
- -
- -
- -
ST Debt
5,368,491
5,545,313
5,900,179
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.33%
2.68%
-5.53%
Free Cash Flow
197.99%
330.49%
-34.65%
Net Income, GAAP
-16.31%
-129.27%
-532.03%
Sales/Revenue/Turnover
8.09%
2.71%
0.38%
Total Cash Common Dividend
20.3%
14.08%
35.49%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,215,961
7,238,675
7,414,278
7,490,168
27,239,748
2025
6,706,018
6,720,381
7,439,500
5,457,442
27,342,589
2026
7,111,120
7,362,113
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,736
5,879
9,676
-12,547.94
8,250
2025
850
10,147
4,550
-51,214.54
-35,668
2026
5,107
-846
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
668.56
4,074.08
1,655.62
1,590.87
7,985.29
2025
815.1
5,332.46
2,321.14
2,354.79
10,826.93
2026
786.88
3,804.56
- -
- -
- -

Company Description

CEO
Seok-hwan Yoon
Full Time Employees
8,232
Sector
Transportation
Industry
Air freight/Couriers
Address
CJ CheilJedang, 330 Seoul SL South Korea 04560
IPO Date
Sep 28, 2007
Website
cj.co.kr
Business
CJ Cheiljedang Corporation engages in the food and biotechnology industries, operating primarily in South Korea and internationally. It offers a comprehensive range of products including home meal replacements; meat and fishery processing; seasoning and sauces; sweeteners, flour, and cooking oils; seaweed, desserts, and snacks; as well as beverages. The company is also active in biotechnology with products such as amino acids, green proteins, enzymes, plant nutrition and health solutions, specialty biomaterials, microbiome-based drug development for genetic infection diseases, and alternative and cultured proteins. Additionally, CJ Cheiljedang operates in animal feed, livestock, fresh meat businesses, and logistics services including transportation, storage, shipping, and loading/unloading. Founded in 1953 and headquartered in Seoul, South Korea, the company has expanded globally with operations in markets including the U.S., China, Vietnam, Japan, Europe, and more than 100 countries exporting its brands. Recent major developments include strategic investments in expanding manufacturing facilities in North America and Europe with new plants planned in South Dakota (2027) and Hungary (2026) to support growing global demand for K-food products such as kimchi, mandu, and ready-to-eat meals. Despite some operational profit challenges in the B2C sector in 2023-2024, the company has seen strong overseas sales growth, with international revenue approaching half of total sales, and has continued to innovate with new biotechnology solutions and product launches under its well-known brand Bibigo. The company also underwent leadership adjustments focused on stabilizing mid-term growth strategies in early 2024. CJ Cheiljedang operates through multiple segments including Food, Biotechnology, Feed and Care, and Logistics, with recent strategic moves emphasizing global expansion, innovation, and diversification of high-value products.